The global oral thin film drugs market is anticipated to grow at a significant CAGR of 8.7% during the forecast period. The films are a modern addition to the pharmaceutical dosage forms globally. Companies in the market are changing the way supplement dosage is administered to the patients and individuals. For instance, Aavishkar Oral Strips Pvt. Ltd. an Indian company is innovating in products that enable effective delivery mechanisms of supplement dosage as per user convenience. Manufacturers in the global oral thin films market are taking cues from such companies to develop products that include active substances directly into the bloodstream. This improves bio-availability and makes it easier for controlled dosage.

The global inflammatory bowel disease drug market is anticipated to grow at a considerable CAGR of around 4.7% during the forecast period. Pharmaceutical companies are working on developing new therapies and drugs for the treatment of Inflammatory bowel disease. At present, clinical trials are helping to introduce treatment for prolonged inflammatory bowel disease. In inflammatory bowel disease, symptoms occur at definite intervals even if medication is given to the affected person. They are a chronic disease that is cured by treating their symptoms and not the actual disease. Most of the people who are affected by ulcerative colitis undergo surgery. 

The global empty gelatin capsule market is anticipated to grow at a significant CAGR around 8.1% during the forecast period (2022-2028). The gelatin capsules segment dominated the empty capsules market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in R&D activities in the healthcare sector and advantages of gelatin capsules as compared to other drugs delivery forms. There are various advantages of gelatin capsules such as thermo-reversibility & tableting, non-allergenic, viscoelasticity, and biocompatibility. 

The global patient handling equipment market is anticipated to grow at a significant CAGR during the forecast period.  Key companies operating in the industry are highly inclined toward the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansions, and product innovations to remain competitive in the market. Technological advancements are anticipated to drive the growth of the market. Radio-frequency identification  (RFID) is a technology that uses electromagnet fields to automatically identify and track the tags attached to objects.

The global mRNA vaccine is anticipated to grow at a 16% CAGR during the forecast period (2022-2028). Key companies operating in the industry are highly inclined toward the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in September 2020, collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation was taken place to accelerate the manufacturing and delivery of up to an additional 100 million doses of future vaccines for low and middle-income countries as a part of Gavi COVAX  AMC, a mechanism within the COVAX facility. 

The global digestive health supplements market is anticipated to grow at a significant CAGR of around 8.6% during the forecast period 2022-2028. The market is highly competitive with the presence of many players. High investments in R&D activities and product innovation have led them to gain major market share in the global mark. For instance, in March 2021, Pantheryx Inc announced that it had acquired TruBiotics, a probiotic supplement brand, and its trademarks from Bayer HealthCare LLC. The TruBiotics brand joined PanTheryx’s current brands and ingredient offerings, including Life’s First Natural, dairy colostrum, and prebiotics, to create a full spectrum of nutritional supplements that support comprehensive digestive and immune health at all stages of life. 

The global liquid bandage market is anticipated to grow at a substantial CAGR during the forecast period. Product innovations in the liquid bandage marker are anticipated to drive the market. Rise in awareness about personal hygiene and surge in demand for liquid bandages due to its advantages such as non-invasive, rapid wound healing etc. Medical textiles are one of the most important and major growth areas within the technical textiles industry. Many researchers have developed innovative medical bandages. Spray on bandages helps in protecting wounds and delivering life-saving drugs to remote areas where immediate medical care is not available. 

The global gastrointestinal  stent market is anticipated to grow at a considerable CAGR of around 5.5% during the forecast period. Technological innovations in medical science are major drivers for the growth of the GI  stent market in the forecast period. Research is going on to make more promising innovations that can tackle gastrointestinal issues in a safe way. More successful implants are prior commitments for market players. For instance, in July 2020, Endo GI  Medical which is an Israeli company has received approval in the field of gastroenterology. This approval has been granted by the US Food and Drug Administration.

The global lutein and zeaxanthin market is anticipated to grow at a CAGR of around 4% during the forecast period (2022-2028). Key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in April 2019, Dohler Group acquired the majority of shares in Zumos Catalano Aragoneses S.A (ZUCASA). 

The global erythropoietin drug market is anticipated to grow at a considerable CAGR of around 5.6% during the forecast period. R&D departments of companies are working upon to develop biosimilar of erythropoietin drugs. They will prove a market driver in the forecast period as drugs by many pharmaceutical companies are costly. Treatment of chronic kidney disease, anemia caused by cancer needs erythropoietin drugs for increasing hemoglobin levels. Biosimilar will prove to be a low-cost alternative. They are easy to develop and require less time to gain approval as compared to biologics. Biologics are derived from living organisms such as humans, animals, microorganisms, or yeast.